Effects of chemotherapy and radiotherapy on spermatogenesis in humans

被引:280
作者
Meistrich, Marvin L. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
Cancer; chemotherapy; radiotherapy; biologic targeted therapy; spermatogenesis; CHRONIC MYELOID-LEUKEMIA; SPERMATOGONIAL STEM-CELLS; LONG-TERM REDUCTION; SPERM PRODUCTION; RADIATION-THERAPY; INTERFERON-ALPHA; HODGKINS-DISEASE; X-IRRADIATION; IMATINIB; MOUSE;
D O I
10.1016/j.fertnstert.2013.08.010
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Treatment of cancer with chemo- or radiotherapy causes reduction of sperm counts often to azoospermic levels that may persist for several years or be permanent. The time course of declines in sperm count can be predicted by the sensitivity of germ cells, with differentiating spermatogonia being most sensitive, and the known kinetics of recovery. Recovery from oligo-or azoospermia is more variable and depends on whether there is killing of stem cells and alteration of the somatic environment that normally supports differentiation of stem cells. Of the cytotoxic therapeutic agents, radiation and most alkylating drugs are the most potent at producing long-term azoospermia. Most of the newer biologic targeted therapies, except those used to target radioisotopes or toxins to cells, seem to have only modest effects, mostly on the endocrine aspects of the male reproductive system; however, their effects when used in combination with cytotoxic agents have not been well studied. (C)2013 by American Society for Reproductive Medicine.
引用
收藏
页码:1180 / 1186
页数:7
相关论文
共 58 条
[1]   CML in pregnancy and childhood [J].
Apperley, Jane .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2009, 22 (03) :455-474
[2]   Pregnancy among patients with chronic myeloid leukemia treated with imatinib [J].
Ault, P ;
Kantarjian, H ;
O'Brien, S ;
Faderl, S ;
Beran, M ;
Rios, MB ;
Koller, C ;
Giles, F ;
Keating, M ;
Talpaz, M ;
Cortes, J .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1204-1208
[3]   Platelet-Derived Growth Factor Receptor β-Subtype Regulates Proliferation and Migration of Gonocytes [J].
Basciani, Sabrina ;
De Luca, Gabriele ;
Dolci, Susanna ;
Brama, Marina ;
Arizzi, Mario ;
Mariani, Stefania ;
Rosano, Giuseppe ;
Spera, Giovanni ;
Gnessi, Lucio .
ENDOCRINOLOGY, 2008, 149 (12) :6226-6235
[4]   Rapamycin-induced oligospermia [J].
Bererhi, L ;
Flamant, M ;
Martinez, F ;
Karras, A ;
Thervet, E ;
Legendre, C .
TRANSPLANTATION, 2003, 76 (05) :885-886
[5]   Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases [J].
Breccia, Massimo ;
Cannella, Laura ;
Montefusco, Enrico ;
Frustaci, Annamaria ;
Pacilli, Matteo ;
Alimena, Giuliana .
LEUKEMIA RESEARCH, 2008, 32 (03) :519-520
[6]   Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (ZevalinA®) [J].
Chiesa, C. ;
Botta, F. ;
Coliva, A. ;
Maccauro, M. ;
Devizzi, L. ;
Guidetti, A. ;
Carlo-Stella, C. ;
Seregni, E. ;
Gianni, M. A. ;
Bombardieri, E. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (11) :1745-1757
[7]   The determination of reproductive safety in men during and after cancer treatment [J].
Choy, Jeremy T. ;
Brannigan, Robert E. .
FERTILITY AND STERILITY, 2013, 100 (05) :1187-1191
[8]  
CLIFTON DK, 1983, J ANDROL, V4, P387
[9]   Acute effects of interferon-α administration on testosterone concentrations in healthy men [J].
Corssmit, EPM ;
Endert, E ;
Sauerwein, HP ;
Romijn, JA .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 143 (03) :371-374
[10]   High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan:: Comparative dosimetric study for tailored treatment [J].
Cremonesi, Marta ;
Ferrari, Mahila ;
Grana, Chiara Maria ;
Vanazzi, Anna ;
Stabin, Mike ;
Bartolomei, Mirco ;
Papi, Stefano ;
Prisco, Gennaro ;
Martinelli, Giovanni ;
Paganelli, Giovanni ;
Ferrucci, Pier Francesco .
JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (11) :1871-1879